Evidence map›Paper›PMID 27924504›Full record

ArticleJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2016

Clinical features and prognostic factors of small cell lung cancer: A retrospective study in 148 patients.

Qian Cai, Hong-Lan Luo, Xi-Can Gao, Chun-Jin Xiong, Fan Tong, Rui-Guang Zhang, Yu Hu, Gang Wu, Xiao-Rong Dong

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qian CaiCancer Center, Huazhong University of Science and Technology, Wuhan, 430022, China.
Hong-Lan LuoDepartment of Oncology, Huanggang Central Hospital, Huangang, 438000, China.
Xi-Can GaoCancer Center, Huazhong University of Science and Technology, Wuhan, 430022, China.
Chun-Jin XiongCancer Center, Huazhong University of Science and Technology, Wuhan, 430022, China.
Fan TongCancer Center, Huazhong University of Science and Technology, Wuhan, 430022, China.
Rui-Guang ZhangCancer Center, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yu HuInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Gang WuCancer Center, Huazhong University of Science and Technology, Wuhan, 430022, China.
Xiao-Rong DongCancer Center, Huazhong University of Science and Technology, Wuhan, 430022, China. xr.dong@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To better understand the outcomes of small cell lung cancer (SCLC), we examined the clinical features and prognostic factors of SCLC in this study. A total of 148 patients who were diagnosed as having SCLC between January 2009 and December 2013 in Cancer Center of Union Hospital, Wuhan, China, were enrolled and their clinical features and prognostic factors were retrospectively analyzed. Log-rank test and Cox regression model were employed for analysis of prognostic factors. The 1- and 2-year overall survival (OS) rates were 59.7% and 25.7%, respectively, for limited disease (LD) patients whose median survival time (MST) was 16 months. The 1- and 2-year OS rates were 29.5% and 5.3%, respectively, for extensive disease (ED) patients whose MST was 10 months. The univariate analysis and multivariate analysis revealed that age, tumor stage, serum CEA and Ki-67 antigen were significantly correlated to the outcomes of SCLC, and they were significant prognostic factors for SCLC.

Indexed as

AdultAgedAged, 80 and overFemaleHumansKi-67 AntigenLung NeoplasmsMaleMiddle AgedNeoplasm StagingSmall Cell Lung CarcinomaSurvival AnalysisKi-67 Antigenprognosis factorsmall cell lung cancersurvival rate

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.